| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study.
|
J Clin Oncol
|
2008
|
7.89
|
|
2
|
Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study.
|
Arthritis Rheum
|
2002
|
4.69
|
|
3
|
Trends in incidence and mortality in rheumatoid arthritis in Rochester, Minnesota, over a forty-year period.
|
Arthritis Rheum
|
2002
|
4.23
|
|
4
|
Predictors of infection in rheumatoid arthritis.
|
Arthritis Rheum
|
2002
|
3.47
|
|
5
|
Impact and perceptions of mandatory tumor biopsies for correlative studies in clinical trials of novel anticancer agents.
|
J Clin Oncol
|
2006
|
3.31
|
|
6
|
Measured and estimated GFR in healthy potential kidney donors.
|
Am J Kidney Dis
|
2004
|
3.11
|
|
7
|
Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study.
|
J Clin Oncol
|
2005
|
2.83
|
|
8
|
Quality of reporting of modern randomized controlled trials in medical oncology: a systematic review.
|
J Natl Cancer Inst
|
2012
|
2.57
|
|
9
|
Medication reconciliation at hospital discharge: evaluating discrepancies.
|
Ann Pharmacother
|
2008
|
2.57
|
|
10
|
Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial.
|
J Clin Oncol
|
2005
|
2.52
|
|
11
|
Assumptions of expected benefits in randomized phase III trials evaluating systemic treatments for cancer.
|
J Natl Cancer Inst
|
2012
|
2.46
|
|
12
|
Impact of wait times on survival for women with uterine cancer.
|
J Clin Oncol
|
2013
|
2.45
|
|
13
|
Randomized phase II trials: inevitable or inadvisable?
|
J Clin Oncol
|
2010
|
2.02
|
|
14
|
Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands.
|
J Clin Oncol
|
2007
|
1.91
|
|
15
|
Dermopathy of Graves' disease (pretibial myxedema): long-term outcome.
|
J Clin Endocrinol Metab
|
2002
|
1.73
|
|
16
|
Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials.
|
Eur Urol
|
2012
|
1.64
|
|
17
|
Evaluation of adverse events experienced by older patients participating in studies of molecularly targeted agents alone or in combination.
|
Clin Cancer Res
|
2006
|
1.63
|
|
18
|
The position of the polycystic kidney disease 1 (PKD1) gene mutation correlates with the severity of renal disease.
|
J Am Soc Nephrol
|
2002
|
1.60
|
|
19
|
Pharmacist medication assessments in a surgical preadmission clinic.
|
Arch Intern Med
|
2007
|
1.57
|
|
20
|
The association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy.
|
Cancer
|
2011
|
1.55
|
|
21
|
Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma.
|
J Clin Oncol
|
2007
|
1.53
|
|
22
|
Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study.
|
Clin Cancer Res
|
2008
|
1.43
|
|
23
|
Barriers in phase I cancer clinical trials referrals and enrollment: five-year experience at the Princess Margaret Hospital.
|
BMC Cancer
|
2006
|
1.41
|
|
24
|
Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib.
|
J Clin Oncol
|
2007
|
1.40
|
|
25
|
Understanding the attitudes of the elderly towards enrolment into cancer clinical trials.
|
BMC Cancer
|
2006
|
1.33
|
|
26
|
Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada Clinical Trials Group Study.
|
J Clin Oncol
|
2007
|
1.33
|
|
27
|
Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy.
|
Urol Oncol
|
2010
|
1.31
|
|
28
|
Analysis of treatment practices for elderly cancer patients in Ontario, Canada.
|
J Clin Oncol
|
2005
|
1.31
|
|
29
|
Natural history and chemotherapy effectiveness for advanced adenocarcinoma of the small bowel: a retrospective review of 113 cases.
|
Am J Clin Oncol
|
2006
|
1.29
|
|
30
|
Expanded phase II trial of gemcitabine and capecitabine for advanced biliary cancer.
|
Cancer
|
2007
|
1.27
|
|
31
|
Phase I targeted combination trial of sorafenib and erlotinib in patients with advanced solid tumors.
|
Clin Cancer Res
|
2007
|
1.26
|
|
32
|
Small-molecule XIAP inhibitors derepress downstream effector caspases and induce apoptosis of acute myeloid leukemia cells.
|
Blood
|
2005
|
1.24
|
|
33
|
Defining a 0.5-mb region of genomic gain on chromosome 6p22 in bladder cancer by quantitative-multiplex polymerase chain reaction.
|
Am J Pathol
|
2004
|
1.21
|
|
34
|
A prospective comparison of MRI-US fused targeted biopsy versus systematic ultrasound-guided biopsy for detecting clinically significant prostate cancer in patients on active surveillance.
|
J Magn Reson Imaging
|
2014
|
1.21
|
|
35
|
Neuroendocrine tumors of the gastrointestinal tract: a decade of experience at the Princess Margaret Hospital.
|
Am J Clin Oncol
|
2008
|
1.11
|
|
36
|
Identification of small molecules that sensitize resistant tumor cells to tumor necrosis factor-family death receptors.
|
Cancer Res
|
2006
|
1.11
|
|
37
|
Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck.
|
Invest New Drugs
|
2007
|
1.04
|
|
38
|
Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial.
|
J Clin Oncol
|
2006
|
1.03
|
|
39
|
Concurrent gemcitabine and radiotherapy with and without neoadjuvant gemcitabine for locally advanced unresectable or resected pancreatic cancer: a phase I-II study.
|
Int J Radiat Oncol Biol Phys
|
2006
|
1.02
|
|
40
|
Preoperative radiation with concurrent chemotherapy for resectable rectal cancer: effect of dose escalation on pathologic complete response, local recurrence-free survival, disease-free survival, and overall survival.
|
Int J Radiat Oncol Biol Phys
|
2005
|
1.00
|
|
41
|
Outcome of patients who develop acute leukemia or myelodysplasia as a second malignancy after solid tumors treated surgically or with strategies that include chemotherapy and/or radiation.
|
Cancer
|
2008
|
0.99
|
|
42
|
Tolerability of the Intergroup 0099 (INT 0099) regimen in locally advanced nasopharyngeal cancer with a focus on patients' nutritional status.
|
Int J Radiat Oncol Biol Phys
|
2004
|
0.98
|
|
43
|
Adherence to surveillance guidelines after curative resection for stage II/III colorectal cancer.
|
Clin Colorectal Cancer
|
2008
|
0.98
|
|
44
|
Early stopping rules in oncology: considerations for clinicians.
|
Eur J Cancer
|
2011
|
0.98
|
|
45
|
UCN-01 in combination with topotecan in patients with advanced recurrent ovarian cancer: a study of the Princess Margaret Hospital Phase II consortium.
|
Gynecol Oncol
|
2007
|
0.97
|
|
46
|
Potential value of Gleason score in predicting the benefit of cabazitaxel in metastatic castration-resistant prostate cancer.
|
Future Oncol
|
2013
|
0.96
|
|
47
|
Are older cancer patients being referred to oncologists? A mail questionnaire of Ontario primary care practitioners to evaluate their referral patterns.
|
J Clin Oncol
|
2003
|
0.96
|
|
48
|
The impact of an educational DVD on cancer patients considering participation in a phase I clinical trial.
|
Support Care Cancer
|
2007
|
0.93
|
|
49
|
Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study.
|
Breast Cancer Res Treat
|
2014
|
0.92
|
|
50
|
The contents and readability of informed consent forms for oncology clinical trials.
|
Am J Clin Oncol
|
2010
|
0.92
|
|
51
|
Fluorescence in situ hybridization gene amplification analysis of EGFR and HER2 in patients with malignant salivary gland tumors treated with lapatinib.
|
Head Neck
|
2009
|
0.92
|
|
52
|
Are family physician visits and continuity of care associated with acute care use at end-of-life? A population-based cohort study of homecare cancer patients.
|
Palliat Med
|
2013
|
0.91
|
|
53
|
Speech recognition as a transcription aid: a randomized comparison with standard transcription.
|
J Am Med Inform Assoc
|
2003
|
0.91
|
|
54
|
Weekly cyclophosphamide and alternate-day prednisone: an effective, convenient, and well-tolerated oral treatment for relapsed multiple myeloma after autologous stem cell transplantation.
|
Mayo Clin Proc
|
2005
|
0.91
|
|
55
|
"PSA-itis": knowledge of serum prostate specific antigen and other causes of anxiety in men with metaststic prostate cancer.
|
J Urol
|
2002
|
0.88
|
|
56
|
Improving the quality of abstract reporting for phase I cancer trials.
|
Clin Cancer Res
|
2008
|
0.87
|
|
57
|
A Phase 2 study of perifosine in advanced or metastatic breast cancer.
|
Breast Cancer Res Treat
|
2007
|
0.87
|
|
58
|
Chemotherapy with gemcitabine-containing regimens for locally recurrent or metastatic nasopharyngeal carcinoma.
|
Cancer
|
2002
|
0.86
|
|
59
|
Prognostic factors for life expectancy in nonagenarians with nonmelanoma skin cancer: implications for selecting surgical candidates.
|
J Am Acad Dermatol
|
2002
|
0.86
|
|
60
|
Statistical and analytical approaches for assessing biomarkers: new approaches, new technologies, with the same-old rigor for evaluation.
|
Clin Biochem
|
2012
|
0.85
|
|
61
|
Radiation therapy for Bowen's disease of the skin.
|
Int J Radiat Oncol Biol Phys
|
2005
|
0.83
|
|
62
|
Fractionated stereotactic radiotherapy for acoustic neuroma: single-institution experience at The Princess Margaret Hospital.
|
Cancer
|
2007
|
0.82
|
|
63
|
A phase II multi-institutional study assessing simultaneous in-field boost helical tomotherapy for 1-3 brain metastases.
|
Radiat Oncol
|
2012
|
0.81
|
|
64
|
Prognostic impact of C-reactive protein in metastatic prostate cancer: a systematic review and meta-analysis.
|
Oncol Res Treat
|
2014
|
0.80
|
|
65
|
Phase I trial of gemcitabine, doxorubicin and cisplatin (GAP) in patients with advanced solid tumors.
|
Anticancer Drugs
|
2006
|
0.80
|
|
66
|
A phase I/II study of GTI-2040 plus docetaxel as second-line treatment in advanced non-small cell lung cancer: a study of the PMH phase II consortium.
|
J Thorac Oncol
|
2009
|
0.80
|
|
67
|
A multicenter phase II study of "adjuvant" irinotecan following resection of colorectal hepatic metastases.
|
Am J Clin Oncol
|
2005
|
0.79
|
|
68
|
Phase 1 trial design: is 3 + 3 the best?
|
Cancer Control
|
2014
|
0.79
|
|
69
|
Influence of statistician involvement on reporting of randomized clinical trials in medical oncology.
|
Anticancer Drugs
|
2013
|
0.78
|
|
70
|
Expression of EGFR, HER-2/neu and KIT in germ cell tumours.
|
Clin Transl Oncol
|
2010
|
0.78
|
|
71
|
Assessing perfusion changes during whole brain irradiation for patients with cerebral metastases.
|
J Neurooncol
|
2005
|
0.77
|
|
72
|
Data collection in cancer clinical trials: Too much of a good thing?
|
Clin Trials
|
2013
|
0.76
|
|
73
|
The impact of chemotherapy-induced cognitive impairment on the psychosocial adjustment of patients with nonmetastatic colorectal cancer.
|
Clin J Oncol Nurs
|
2012
|
0.76
|
|
74
|
Cardiac and inflammation biomarker profile after initiation of adjuvant trastuzumab therapy.
|
Clin Chem
|
2012
|
0.75
|
|
75
|
The influence of mentorship on research productivity in oncology.
|
Am J Clin Oncol
|
2007
|
0.75
|
|
76
|
The unclear zone in phase II clinical trials.
|
Eur J Cancer
|
2010
|
0.75
|
|
77
|
Thyroid hormone receptor α in breast cancer: prognostic and therapeutic implications.
|
Breast Cancer Res Treat
|
2014
|
0.75
|
|
78
|
Do beta-blockers alter dyspnea and fatigue in advanced lung cancer? A retrospective analysis.
|
Palliat Med
|
2011
|
0.75
|
|
79
|
A phase I study of pegylated liposomal doxorubicin hydrochloride (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small-cell lung cancer.
|
Clin Lung Cancer
|
2003
|
0.75
|